Russell Investments Group Ltd. reduced its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 6.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,268 shares of the company’s stock after selling 9,363 shares during the period. Russell Investments Group Ltd. owned 0.06% of Revolution Medicines worth $27,149,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Alphabet Inc. acquired a new stake in Revolution Medicines during the 2nd quarter worth $551,843,000. Assenagon Asset Management S.A. raised its stake in Revolution Medicines by 987.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock worth $447,710,000 after purchasing an additional 1,980,699 shares during the period. ABS Investment Management LLC acquired a new position in Revolution Medicines in the second quarter valued at approximately $337,104,000. Bank of America Corp DE acquired a new stake in Revolution Medicines during the second quarter worth $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Revolution Medicines by 82.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock worth $170,862,000 after acquiring an additional 411,740 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.
Insider Buying and Selling at Revolution Medicines
In related news, Director Elizabeth M. Anderson sold 10,143 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total value of $1,958,004.72. Following the transaction, the director owned 4,333 shares in the company, valued at $836,442.32. The trade was a 70.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Mark A. Goldsmith sold 13,988 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the completion of the transaction, the insider directly owned 253,342 shares in the company, valued at $50,475,860.08. This represents a 5.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 326,741 shares of company stock valued at $66,147,340. 7.60% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Piper Sandler upped their price target on Revolution Medicines from $210.00 to $222.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Truist Financial reissued a “buy” rating and set a $261.00 price objective (up from $241.00) on shares of Revolution Medicines in a research report on Thursday, November 5th. William Blair started coverage on Revolution Medicines in a research report on Friday, October 16th. They set an “outperform” rating for the company. Oppenheimer boosted their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Finally, Evercore reaffirmed an “outperform” rating and issued a $320.00 target price on shares of Revolution Medicines in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $262.75.
Get Our Latest Analysis on Revolution Medicines
Latest Revolution Medicines News
Investors following RVMD have been watching these news items:
- Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and $350 price target, signaling substantial potential upside in the analyst’s view. HC Wainwright rating information
- Negative Sentiment: RVMD’s CFO reportedly sold about $6.7 million in company shares, a transaction that may concern investors, though insider sales alone do not establish a change in the company’s outlook. CFO stock sale report
- Negative Sentiment: Morgan Stanley reportedly trimmed its price target for RVMD, providing a more cautious analyst signal; the available report does not specify the revised target. Morgan Stanley price-target report
Revolution Medicines Stock Down 2.5%
NASDAQ:RVMD opened at $162.69 on Wednesday. The stock’s fifty day moving average is $192.71 and its two-hundred day moving average is $160.09. Revolution Medicines, Inc. has a 52 week low of $67.86 and a 52 week high of $224.31. The stock has a market capitalization of $35.19 billion, a price-to-earnings ratio of -17.86 and a beta of 1.44. The company has a quick ratio of 8.34, a current ratio of 8.36 and a debt-to-equity ratio of 0.44.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The firm had revenue of $197.56 million for the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter in the previous year, the company posted ($1.61) earnings per share. Research analysts anticipate that Revolution Medicines, Inc. will post -7.41 EPS for the current year.
Revolution Medicines Company Profile
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
Featured Stories
- Five stocks we like better than Revolution Medicines
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
